Complex genetic mutations are common in brain cancer, making gene therapy an attractive approach to repair or modulate altered genes and cellular pathways. We engineered a pHresponsive DNA nanoparticle platform designed to protect DNA from degradation in vivo, enable efficient intracellular trafficking and transgene expression, and tested the ability of this system to knockdown a model gene in brain tumors.
INTRODUCTION
Highly compacted DNA nanoparticles, composed of single molecules of plasmid DNA compacted with block copolymers of polyethylene glycol and poly-L-lysine (CK 30 PEG), represent a promising non-viral technology that has demonstrated remarkable effectiveness in delivering genes to the brain, eyes and lungs with minimal toxicity and immunogenicity. 1, 2 With the growing knowledge of the complex genetic alterations and subtypes in Glioblastoma (GBM), modulation of defective and malfunctioning genes, cellular pathways, and the tumor microenvironment is increasingly viewed as a promising approach. The clinical development of non-viral vectors has been hindered in part by relatively low gene transfer efficiencies compared to viral vectors. This may be due to the inability to tolerate or overcome various biological barriers. A particularly challenging barrier involves endo-lysosomal trafficking within cells, where therapeutic DNA is often degraded in the acidic and enzyme-rich late endosomes and lysosomes before reaching the nucleus.
To overcome this potential shortcoming, we engineered a pH-responsive DNA nanoparticle platform designed to protect DNA from 3 degradation in vivo, enable efficient intracellular trafficking and transgene expression, and tested the ability of this system to knockdown a model gene in brain tumors.
EXPERIMENTAL METHODS
We developed pH-responsive DNA nanoparticles, CH 12 K 18 PEG 5k , by inserting a poly-L-histidine segment between PEG and poly-L-lysine to engineer a triblock copolymer. A copolymer containing 5 kDa polyethylene glycol, 18-mer poly-L-lysine, and 12-mer poly-L-histidine, CH 12 K 18 PEG 5k , was chosen based on nanoparticle physicochemical characteristics and DNA protection. Using this polymer, DNA nanoparticles were formulated using a reporter plasmid (GFP, shLuciferase RNAi). GL261 mouse glioma cells were stably transfected with the firefly luciferase gene to enable in vivo bioluminescent imaging of a tumor-specific transgene (Xenogen IVIS). DNA nanoparticles were directly applied to glioma cells in culture and to intracranial tumors in vivo. Intracellular trafficking of nanoparticles in glioma cells were performed using fluorescently-labeled DNA nanoparticles, endosome-specific labeling dyes, and endocytic pathway inhibition agents.
RESULTS AND DISCUSSION
CH 12 K 18 PEG 5k compacted DNA into rodshaped DNA nanoparticles with similar morphology and colloidal stability as CK 30 PEG DNA nanoparticles. The triblock copolymer design of CH 12 K 18 PEG 5k DNA nanoparticles ensured that a neutral surface charge is maintained by the PEG chains and that poly-Lhistidine is localized in an intermediate layer, where it is available to buffer pH without interfering with DNA compaction. Inclusion of poly-L-histidine increased the buffering capacity of CH 12 K 18 PEG 5k to levels comparable with branched polyethyleneimine (Table 1) . Intracellular trafficking and uptake inhibition experiments revealed clathrin-dependent endocytosis as the primary pathway for DNA nanoparticle internalization in brain tumor cells. CH 12 K 18 PEG 5k DNA nanoparticles efficiently protected plasmid DNA from both DNasemediated and acidic lysosomal degradation. CH 12 K 18 PEG 5k DNA nanoparticles effectively silenced a tumor-specific transgene (firefly luciferase) following direct injection into mouse intracranial gliomablastoma (Figure 1 ). Toxicity and histological analysis showed no evidence of acute or delayed inflammatory responses. Our results demonstrate the utility of using this DNA nanoparticle-based technology for delivering genes to tumor cells as a possible therapeutic approach for patients with brain cancer. . a DNA compacted with CK 30 PEG or CH 12 K 18 PEG were formulated at pH 7.5 and at a final lysine to phosphate ratio (N:P) of 2:1. PEI DNA nanoparticles were formulated at pH 7.4 and at a final N:P ratio of 10:1. b Diameter (number mean) measured by dynamic light scattering. Data represents the average of 3 independent experiments +/-SD. c Measured at pH 7.1. Data represents the average of 3 independent experiments +/-SD. d Buffering capacity, as measured by acid-base titration, represents the percentage of (protonable) amine groups becoming protonated from pH 7.4 to 5.1. Data represents the average of 3 independent experiments +/-SD. * denotes statistical significance (* P < 0.05, GamesHowell) as compared to CK 30 PEG.
CONCLUSION
Using highly compacted pH-responsive DNA nanoparticles, a tumor-specific transgene could be effectively silenced in vitro and in vivo.
CH 12 K 18 PEG 5k DNA nanoparticles trafficked through CME in mouse glioblastoma cells, and protected plasmid DNA from both DNase-mediated and acidic lysosomal degradation. These results support further investigation into the use of these promising non-viral, polymer-based CH 12 K 18 PEG 5k DNA nanoparticles in brain tumors. 
